CAMP4 Therapeutics Corporation Retained Earnings
CAMP4 Therapeutics Corporation (CAMP) had Retained Earnings of -$344.02 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$344.02M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$310.49M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$292.16M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$251.87M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$344.02M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$310.49M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$292.16M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$251.87M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$236.77M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$224.19M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$211.75M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$198.47M 10-Q · filed 2024-11-21 |
| 2023-12-31 | -$159.96M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |